This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/stock-market-movers-9cc9fac3 Updated July 25, 2023…
Read more F5, Logitech, Cadence Design, GE, GM, Microsoft, Alphabet, and More Stock Market MoversThe U.S. Food and Drug Administration on Thursday granted full approval to the Biogen BIIB and Eisai Co. Ltd. ESALF Alzheimer’s treatment Leqembi, a step that secures Medicare…
Read more FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverageThe U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.’s torferson, a treatment for a rare form of amyotrophic lateral sclerosis, or…
Read more Biogen wins accelerated FDA approval for treatment for rare form of ALSBiogen’s Alzheimer’s Drug Could be Expensive Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s reported on Friday,…
Read more BIIB Stock Price | Biogen Inc. Stock Quote (U.S.: Nasdaq) | MarketWatchBiogen’s Alzheimer’s Drug Could be Expensive Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s reported on Friday,…
Read more BIIB Stock Price | Biogen Inc. Stock Quote (U.S.: Nasdaq) | MarketWatchBiogen Inc. shares BIIB, +5.07% rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer’s disease failed to meet…
Read more Biogen shares jump 4.7% premarket on hopes for its Alzheimer’s treatment lecanemab
